

# 2 0 2 4

More Information: www.oxfordglobal.com



Linked in 🔆



## 

In recent years, spatial biology technologies have emerged as a powerful tool in the field of medical diagnostics. These innovative techniques allow researchers and clinicians to analyse the spatial organization of cells and tissues, providing valuable insights into disease progression, treatment response, and patient outcomes. With the potential to revolutionize clinical practice, it is crucial to understand the advancements, challenges, and future prospects of spatial technologies in the clinic.

At Oxford Global, we keep a close eye on innovations, technological advancements and evolving market opportunities. We are delighted to present you this insightful report that delves into the transformative potential of spatial technologies in the realm of healthcare through the eyes of six experts in the field sharing their top tips, invaluable insights and strategies on how spatial technologies are reshaping the future of clinical practices.

### 6 Top Tips Exploring the Acceleration of Spatial Technologies towards the Clinic – Expert Perspectives

Throughout this e-book, you will have the opportunity to journey through the thoughts and experiences of our esteemed panel of experts. Each expert brings a unique perspective, offering invaluable hints and tips on how spatial technologies can be harnessed and integrated into clinical settings seamlessly bringing us closer to the question: how far are we from the adoption of spatial technologies in the clinic?

Discover the latest advancements in high-resolution platforms, computational analysis techniques, and cutting-edge applications in the study of diseases such as pulmonary disorders, oncology, and beyond. Gain profound insights into the diverse clinical applications of spatial technologies and understand how they are poised to revolutionize patient care.

The insights shared in this e-book are more than just expert opinions; they are the building blocks for the future of healthcare. We invite you to dive deep into the wisdom shared by these experts, absorbing their insights, advice and practical tips, and envisioning a future where spatial technologies pave the way for more accurate diagnoses, targeted treatments, and ultimately, improved patient outcomes. Let the insights within these pages inspire you and fuel your passion for pioneering advancements in the world of healthcare.



Eszter Sutowski Nagy, Director of Editorial & Event Content, Oxford Global

## CONTENTS

- Pg.1) EVAN KELLER, Director, Single Cell Spatial Analysis Program and Professor of Urology and Pathology, University of Michigan
- Pg.2) RAFFAELE CALOGERO, Professor, University of Turin
- Pg.4) YAN TANG, Instructor in Medicine, Harvard University

- Pg.5) CHARLOTTE STADLER, Co-Director SSCB Platform and Head of Spatial Proteomics Unit, SciLifeLab
- Pg.7) MIAO PING CHIEN, Principal Investigator, ERASMUS
- Pg.9) JOHN WATERTON, Professor, The University of Manchester



## EVAN KELLER, Director, Single Cell Spatial Analysis Program & Professor of Urology and Pathology, University of Michigan

Professor Keller explains that in recent years, spatial biologic technologies have emerged as a powerful tool in the field of medical diagnostics. These innovative techniques allow researchers and clinicians to analyze the spatial organization of cells and tissues, providing valuable insights into disease progression, treatment response, and patient outcomes. With the potential to revolutionize clinical practice, Professor Keller thinks it is crucial to understand the advancements, challenges, and future prospects of spatial technologies in the clinic. In this article, we will explore the exciting progress made in this field, the key factors driving adoption, the limitations and barriers to overcome, and the potential impact on patient care.

## TIP 1: Understanding the Mechanisms of Spatial Biology Technologies

Spatial technologies combine single-cell transcriptomics or proteomics with spatial context, providing a comprehensive understanding of gene and protein expression patterns within tissues. By integrating spatial information, researchers can identify specific cell types, their spatial relationships, and gene expression profiles at a single-cell level. This multidimensional approach offers unique insights into cellular interactions, tissue heterogeneity, and disease mechanisms.

Professor Keller highlights that in recent years, significant advancements have been made in spatial biology technologies. One such breakthrough is the marriage of single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics, enabling the simultaneous analysis of gene expression at the single-cell level while preserving the spatial context. This integration has opened new avenues for understanding disease pathology and has the potential to revolutionize clinical diagnostics.

The Evolution of Spatial Technologies

The journey of spatial biologic technology began with the advent of single-cell RNA sequencing (scRNA-seq) and transcriptomics. Early on, researchers realized the limitation of scRNA-seq techniques, as they lacked spatial information. Professor Keller explains this led to the development of spatial technologies

that could bridge this gap and provide a more comprehensive understanding of cellular interactions within tissues.

According to Professor Keller, one of the pioneering commercial technologies in the field of spatial transcriptomics was the 10x Genomics Visium platform, which allowed for resolution of approximately 10 cells.

This technology offered the ability to process large cell numbers in spatial context marking a significant step forward in spatial biologic research. However, there was desire to increase the accuracy of these methods to true single cell resolution.

Subsequently, the introduction of technologies like 10x Genomics Xenium and Nanostring CosMx further enhanced the field's capabilities. These technologies offer tru single cell transcriptomic resolution, expanding the range of studies possible. These advancements, coupled with the integration of proteomics and mass spectrometry imaging, have propelled spatial biologic technology forward, paving the way for its potential application in clinical settings.

### **TIP 2: Unlocking The Clinical Potential of Spatial Technologies**

Professor Keller explains that while spatial biologic technology is still in its early stages of adoption in clinical settings, it holds immense

promise for various medical specialties. Cancer research is one area where spatial technologies are expected to have a significant impact. The ability to analyze the immune microenvironment and understand tumor heterogeneity can provide valuable insights into cancer prognosis and treatment response.

Immunotherapy, in particular, stands to benefit from spatial technologies. By examining the spatial relationships between immune cells and cancer cells, researchers can predict the effectiveness of immunotherapy and tailor treatment strategies accordingly. This precision medicine approach has the potential to improve patient outcomes and reduce unnecessary treatment-related side effects.

Beyond cancer, spatial technologies have the potential to revolutionize other fields such as neurology, neuroscience, and inflammatory diseases. In neurology, analyzing neuronal connections and spatial organization could lead to a better understanding of neurological disorders and the development of targeted therapies. Similarly, in inflammatory diseases like arthritis, spatial information can inform treatment strategies by identifying the most effective therapeutic approaches based on the microenvironment.

### TIP 3: Addressing the Biological Complexity of Diseases; Generation of Spatial Signatures & Logistical Considerations

Professor Keller believes that while the potential of spatial technologies in clinical diagnostics is promising, several challenges must be overcome for widespread adoption. One of the major challenges lies in the biological complexity of diseases. Tumor heterogeneity, for example, poses a significant challenge in accurately identifying spatial signatures and developing reliable biomarkers. The diverse cellular composition within tumors can lead to variations in







## EVAN KELLER, Director, Single Cell Spatial Analysis Program & Professor of Urology and Pathology, University of Michigan

gene expression patterns, necessitating the development of robust analytical methods.

Another challenge according to Professor Keller is the generation of spatial signatures. To develop accurate spatial biomarkers, largescale studies involving hundreds of samples are required. However, conducting such studies can be costly and time-consuming. Additionally, the technical limitations of current spatial technologies, such as limited probe sets and low resolution, hinder the comprehensive analysis of gene expression patterns.

Logistical considerations also pose challenges to the adoption of spatial technologies in clinical settings. The processing of tissues, obtaining fresh tissue samples, and the availability of instruments and expertise are critical factors. As Professor Keller highlights, the analysis of large datasets generated by spatial technologies requires advanced bioinformatics capabilities, which are currently lacking in many clinical settings.

Efforts are underway to address the limitations of spatial technologies and advance their clinical applications. Researchers are working on expanding the probe sets to enable the analysis of a wider range of genes. The development of more efficient software solutions for data analysis and interpretation is also a priority.

Improving the repeatability and accuracy of spatial technologies is crucial. This involves refining tissue processing techniques, enhancing the resolution of spatial analysis, and developing standardized protocols for sample preparation. Professor Keller adds that collaborations between bioinformaticians and clinicians are essential to ensure the accurate interpretation of spatial data and its integration into clinical decision-making.

Professor Keller highlights that artificial

intelligence (AI) is expected to play a significant role in the future of spatial technologies. Al algorithms can aid in the analysis of complex spatial datasets, identify patterns, and predict disease outcomes. Integrating AI into spatial technology platforms can streamline data analysis and facilitate the translation of research findings into clinical practice.

## **TIP 4: Developing Robust Spatial Biomarkers** & Validation Through Clinical Trials

According to Professor Keller, despite the challenges and limitations, the path to clinical adoption of spatial technologies is steadily progressing. The development of robust spatial biomarkers and their validation through clinical trials is a crucial step in this process. These biomarkers can aid in disease diagnosis, prognosis, treatment selection, and monitoring of therapeutic response.

Realizing the full potential of spatial technologies in the clinic will require collaboration among researchers, clinicians, bioinformaticians, and regulatory bodies; explains Professor Keller. Standardization of protocols, data sharing initiatives, and the establishment of quidelines for spatial analysis are vital in ensuring the reproducibility and reliability of results.

The adoption of spatial technologies in the clinic is expected to occur gradually over the next five to ten years. As research advances, the identification of spatial signatures and their integration into clinical practice will become more commonplace. This will enable clinicians to make more informed decisions. tailor treatments to individual patients, and improve overall patient care.

## TIP 5: Optimising Patient Care In Oncology And Beyond

As Professor Keller highlights, the integration of spatial technologies into clinical practice has the potential to revolutionize patient care. By providing a deeper understanding of disease biology, spatial technologies can assist in accurate diagnosis, prognosis, and treatment selection. This precision medicine approach ensures that patients receive the most effective therapies while minimizing unnecessary treatments and side effects.

In the field of oncology, spatial technologies can guide treatment decisions, particularly in immunotherapy. By identifying the spatial relationships between immune cells and cancer cells, clinicians can predict the efficacy of immunotherapy and select the most appropriate treatment strategy for each patient. This personalized approach improves patient outcomes and enhances the efficiency of healthcare resources.

Furthermore, spatial technologies can aid in the identification of disease subtypes and the characterization of tumor heterogeneity. By analyzing spatial gene expression patterns, clinicians can refine disease classification, predict disease progression, and identify potential therapeutic targets. This comprehensive understanding of disease biology translates into improved patient care and outcomes.

### Final Remarks from Professor Keller:

Professor Keller strongly believes that spatial technologies have the potential to transform clinical diagnostics and patient care. As the field continues to evolve, advancements in probe sets, resolution, and data analysis will enhance the accuracy and reproducibility of spatial technologies. The integration of AI algorithms and the standardization of protocols will further facilitate the adoption of spatial technologies in clinical settings.

While challenges remain, ongoing research and collaborations among multidisciplinary teams hold the key to overcoming these obstacles. By addressing the limitations of spatial technologies and ensuring their reliability, the path to clinical adoption can be paved. Ultimately, the widespread integration of spatial technologies in the clinic will enable clinicians to provide personalized, targeted therapies and improve patient outcomes.

In conclusion, spatial technologies represent a breakthrough in medical diagnostics, with the potential to revolutionize clinical practice. By harnessing the power of spatial analysis, researchers and clinicians can unlock valuable insights into disease mechanisms, treatment response, and patient outcomes. With continued advancements and collaborations, spatial technologies will shape the future of precision medicine, offering patients tailored therapies and improved healthcare outcomes.





## **RAFFAELE CALOGERO,** Professor, University of Turin

## TIP 1: Embracing Adaptive Platforms

Professor Raffaele Calogero's experiences underscore the intricate decision-making process researchers face when choosing platforms in the rapidly evolving field of spatial biology. As Professor Calogero points out, the dilemma revolves around investing in instruments that might quickly become outdated due to technological advancements. The strategic choice of platforms, such as the next genomic vision platform, highlights the importance of adaptability. These platforms, designed to work seamlessly with conventional laboratory instruments, provide researchers with the flexibility needed to keep pace with ever-changing technologies. This adaptive approach ensures that research endeavours remain relevant and do not succumb to obsolescence.

## TIP 2: Establishing Benchmark Experiments

One of the critical challenges in spatial biology is the absence of specific benchmarks dedicated to evaluating the performance of spatial transcriptomics technologies. Professor Calogero's work emphasizes the necessity of these benchmark experiments.

By creating standardized tests tailored to spatial transcriptomics, researchers can effectively assess the accuracy, reliability, and efficiency of various technologies.

These benchmarks not only validate existing platforms but also provide a foundation upon which future innovations can thrive. As researchers develop these standardized tests, they set a precedent for quality assurance within the spatial biology domain.

## 🔆 TIP 3: Fostering Collaborations and Knowledge Sharing

In the pursuit of advancing spatial biology, collaboration plays a pivotal role. Professor Calogero's team operates as a core facility, offering invaluable support to fellow researchers. This collaborative approach fosters a sense of community within the scientific research sphere. By sharing expertise and resources, researchers can amplify the impact of their work. The core facility model exemplifies the synergy that arises when scientists come together, driving innovation and accelerating progress in spatial biology research.

## TIP 4: Addressing Costs

While the promise of spatial technologies in clinical settings is undeniable, significant hurdles remain. High costs and the absence of specialized clinical applications pose challenges to widespread adoption. Addressing these issues requires concerted efforts from both researchers and industry professionals. Innovations aimed at cost reduction, along with the development of applications tailored for clinical use, are imperative. Overcoming these hurdles is essential to realizing the full potential of spatial technologies in improving patient outcomes and transforming healthcare practices.

## TIP 5: Envisioning Future Applications

Looking forward, Professor Calogero's optimism about the future of spatial technologies shines through. Anticipated advancements within the next five years underscore the rapid pace of development. Moreover, the prospect of delving into spatial metabolomics hints at the potential for groundbreaking discoveries. Unraveling the intricate relationships between molecules within cells promises to deepen our understanding of biological systems. Simultaneously, exploring cell interactions at unprecedented resolutions signifies a paradigm shift in biology. These future applications hold the promise of reshaping scientific inquiry, medical diagnostics, and therapeutic interventions. The path forward in spatial biology is laden with potential, offering a tantalizing glimpse into a future where cellular mysteries are unlocked with unparalleled precision.

## Precision Oncology: Revolutionizing Cancer Research

A focal point of Professor Calogero's insights lies in the realm of oncology. Spatial technologies have the potential to revolutionize cancer research and treatment strategies. By unraveling the complexities of cell interactions and protein expressions within tumors, researchers gain unprecedented insights. These nuanced understandings pave the way for precision oncology, wherein therapies can be tailored with exquisite specificity. The identification of precise targets within tumors heralds a new era in cancer treatment, promising higher efficacy and reduced side effects. Spatial technologies thus emerge as indispensable tools in the fight against cancer.







# YAN TANG, Instructor in Medicine, Harvard University

## TIP 1: Unlocking the Full Potential of Spatial Technologies

Dr Tang explains that spatial technologies enable researchers to study the spatial organization of cells and tissues in unprecedented detail, providing valuable insights into the complex interactions that occur within the human body. With the potential to transform clinical diagnostics, patient care, and therapeutic development, spatial technologies are being rapidly adopted and advanced. As Dr Tang explains, traditional single-cell analysis techniques, such as droplet-based single-cell analysis, have provided valuable insights into cellular characteristics and gene expression patterns. However, these techniques have limitations when it comes to understanding the spatial relationships between cells within a tissue. Spatial technologies aim to address these limitations by providing a platform for highresolution, high-throughput analysis of the spatial organization of cells and tissues.

### TIP 2: Diversifying the Range of Clinical Applications for Spatial Technologies

According to Dr Tang, the potential applications of spatial technologies in clinical settings are vast and promising. By enabling researchers to study the spatial relationships between cells and tissues, these technologies offer valuable insights into disease progression, therapeutic targets, and patient outcomes. One area where spatial technologies show great promise is in the field of pulmonary disease. Researchers have already identified the ability to visualize the organization of fibrosis and cystic regions, providing a better understanding of disease mechanisms and potential treatment options.

Spatial technologies also hold significant potential in the study of primary lung cancer and kidney tumors. By analyzing the spatial context of these tumors, researchers can gain insights into the tumor microenvironment and interactions with surrounding cells. This information can help identify potential therapeutic targets and improve patient outcomes.

### TIP 3: Solving the Puzzle of Spatial Resolution & Costs

Dr Tang believes that while spatial technologies offer tremendous potential, there are still some limitations that need to be addressed for their broader adoption in clinical settings. One significant limitation is the resolution of current platforms. The commercially available platforms have a resolution ranging from one to ten cells per spot, which can lead to challenges in accurately identifying specific cell types within a tissue. However, advancements in technology, such as the development of high-resolution platforms, are being pursued to overcome this limitation. Another limitation of current spatial technologies is the cost associated with their implementation in clinical applications. The high cost of these technologies can hinder their widespread adoption and limit their use in routine clinical diagnostics. Addressing this limitation will require advancements in technology and manufacturing processes to reduce the cost of these platforms.

## TIP 4: Gaining a Comprehensive Understanding of Diseases through Spatial Technologies

The adoption of spatial technologies in a clinical setting is driven by several factors, Dr Tang explains. One of the most significant factors is the ability of these technologies to provide insights into how cells interact with each other in disease conditions. By studying the spatial organization of cells, researchers can gain a deeper understanding of disease mechanisms and identify potential therapeutic targets. This information is valuable for healthcare providers in developing personalized treatment plans for patients.

Another driving factor for the adoption of spatial technologies is the ability to understand the nature of diseases in a spatial context. Traditional single-cell analysis techniques provide valuable information about individual cells, but spatial technologies allow researchers to study the community of cells and their interactions within a tissue. This broader perspective enhances our understanding of diseases and can lead to more effective treatment strategies.

## TIP 5: Focusing on High-Resolution Platforms and Advanced Computational Analysis

Dr Tang highlights that in order to overcome the current limitations of spatial technologies, advancements are being made in several areas. One area of focus is the development of highresolution platforms that can provide more detailed spatial information. These platforms aim to offer a better understanding of cellular interactions and improve the accuracy of identifying specific cell types within a tissue. Additionally, efforts are being made to improve the computational analysis of spatial data. While significant progress has been made in the analysis of single-cell data, computational analysis of spatial data is still relatively limited. Researchers are working on developing specific programs and algorithms to analyse spatial data and extract meaningful insights. This advancement will enhance our ability to interpret spatial information and its implications in clinical settings.

## Final Remarks from Dr Tang:

Spatial technologies have the potential to revolutionize healthcare by providing a deeper understanding of cellular interactions and disease mechanisms. By studying the spatial organization of cells and tissues, researchers can uncover valuable insights that can inform clinical diagnostics, patient care, and therapeutic development. While there are challenges to overcome, advancements in technology and computational analysis are paving the way for the accelerated adoption of spatial technologies in clinical settings. With further research and development, spatial technologies will continue to shape the future of healthcare and improve patient outcomes.







# CHARLOTTE STADLER, Co-Director SSCB Platform & Head of Spatial Proteomics Unit, SciLifeLab

In the rapidly evolving field of healthcare, the integration of spatial technologies has emerged as a game-changer in precision medicine. These cutting-edge methods, such as spatial transcriptomics and proteomics, offer clinicians an unprecedented understanding of the tumor microenvironment and hold promise for tailored treatments for patients. Charlotte Stadler's team is heavily involved in exploring the potential of spatial technologies in the clinical setting, the challenges associated with their adoption, and the factors that determine their long-term success and sustainability.

### TIP 1: Understanding Spatial Biology and Spatial Technologies Better

Dr. Stadler explains that spatial biology, a field that investigates the spatial organization of biomolecules in tissues, has gained significant traction in recent years. By analyzing the location and interactions of cells and molecules within an intact tissue sample, spatial technologies provide a comprehensive understanding of the underlying biological processes and the tissue microenvironment. This deeper insight open up new avenues for clinicians to develop personalized treatment strategies and improve patient outcomes. According to Stadler, one of the key spatial technologies, spatial transcriptomics, allows researchers to visualize global or targeted gene expression patterns in the spatial context. By mapping gene expression levels across tissue sections, scientists can identify the specific cell types and their distribution in various diseases. This information is crucial for unravelling the complexities of tumor biology and potentially developing new targeted therapies. Similarly, spatial proteomics focuses on the spatial distribution of proteins within tissues, allowing for detailed mapping of cellular phenotypes and states. In cancer this is relevant as it gives insight into the degree of infiltrating immune cell populations within a

tumor. Which has shown to often correlate with prognosis and certain treatment outcomes. Spatial proteomics, or highly multiplexed imaging of proteins, is likely closer to clinical implementation as imaging of proteins has been used within clinic for decades along with hemotoxylin and eosin stains for morphological assessment of the tissue samples. The great benefit with these new multiplexing technologies is the ability to simultaneously identify many more protein markers within the same sample. Further, adequate diagnosis of the primary tumour can be achieved in shorter time, compared to standard single plex immunohistochemistry, that has been the golden standard in image based pathology. Therefore, spatial proteomics is to be considered the next era in image-based pathology. By integrating spatial proteomics with other omics data, clinicians can develop an even more comprehensive understanding of disease progression and response to therapy. However these integrated omics methods will take longer to implement and much research is needed to identify gene and protein panels of clinical significance.

### **TIP 2:** The Promise of Spatial Technologies in Precision Medicine

Dr. Stadler highlights that the adoption of spatial technologies in the clinical setting holds immense promise for improving patient care. One of the primary areas where these technologies show great potential is in the field of immunotherapy, particularly in the context of cancer treatment. Immunotherapies have revolutionized cancer care, but their efficacy varies widely among patients. By leveraging spatial technologies, clinicians can identify predictive markers that determine which patients are likely to respond to specific immunotherapies. This personalized approach reduces over-treatment and minimizes unnecessary side effects, ultimately improving patient outcomes.Moreover, spatial

technologies enable a deeper understanding of the tumor microenvironment, which plays a crucial role in cancer progression and treatment response. By analyzing the spatial distribution of immune cells, stromal cells, and tumor cells, clinicians can identify key interactions and molecular signaling pathways that drive disease progression. This knowledge allows for the development of targeted therapies that disrupt these pathways and improve treatment efficacy.

### **TIP 3:** Challenges in the Adoption of Spatial Technologies: Regulatory **Considerations & Data Analysis**

As Dr Stadler explains, while the potential of spatial technologies in precision medicine is undeniable, several challenges hinder their widespread adoption in the clinical setting.

Regulatory considerations pose a significant barrier, as the integration of new technologies requires rigorous validation and adherence to established standards. The transition from research to clinical application necessitates robust protocols, automation, and scalability. These factors ensure that spatial technologies can be seamlessly incorporated into existing clinical workflows, enabling broad accessibility and reproducibility.

Another challenge lies in the interpretation of the vast amount of data generated by spatial technologies. Researchers are accustomed to generating large datasets, but translating these findings into clinically actionable insights requires a different approach. Clinicians require clear, concise, and standardized information that provides a "yes" or "no" answer regarding treatment decisions. Bridging the gap between research findings and clinical significance is crucial for the successful implementation of spatial technologies in precision medicine.









# CHARLOTTE STADLER, Co-Director SSCB Platform & Head of Spatial Proteomics Unit, SciLifeLab

## TIP 4: Improved Predictive Tools & Cost-Effectiveness

Despite the challenges, the adoption of spatial technologies in the clinical setting is driven by several factors. The primary driver is the proven need for improved predictive tools in healthcare. Clinicians strive to identify patients who will benefit from specific treatments and avoid unnecessary interventions. The success of next-generation sequencing methods in uncovering genetic mutations and genotypes, has paved the way for the implementation of sequencing patient samples using targeted gene panels for various cancer types and the mqturation of the technologies has reduced the costs while proving their clinical value. Spatial technologies, which offer a complementary approach to understanding disease mechanisms and treatment response and will likely follow the same route as the sequencing.

Cost-effectiveness is another critical factor in the adoption of spatial technologies. While the initial investment may be significant, the long-term benefits, such as improved patient outcomes and reduced healthcare costs and time, make these technologies highly valuable. As an example, performing a 10-plex spatial proteomics experiment today to diagnose a primary lung cancer tumour, will of course be more expensive compared to performing a conventional single plex IHC staining for a diagnostic marker. However, when this first staining fails to give conclusive results and staining of additional markers are needed, the total cost and time for the diagnosis is much higher and together have a higher price than performing the single 10 -plex staining. Demonstrating the cost-effectiveness and clinical utility of spatial technologies is key to garnering support from healthcare providers and policymakers.

## TIP 5: The Importance of Team Science and Education of Future Clinicians

We are truly in the era of fast development of new technologies within the life science field. Many of these methods have or will become implemented into the healthcare system. Some technologies will primarily modernise already implemented workflows and diagnostics – such as multiplexed imaging of proteins, while others will introduce completely new types of information that can be obtained from the patient samples, such as the spatial distribution of transcripts or looking at protein-protein interactions to infer cell signalling events.

As these methods often become more and more advanced and require technical expertise to leverage on their potential, effort must be put into educating the clinicians and decision makers to better understand the value and rationale behind these technologies. This does not mean they will become experts in the methods, however learning and becoming aware of all new methods will facilitate their implementation into clinical practise.

In the clinical setting, the spatial omics methods have great potential to aid treatment decisions, benefit the patients and save resources in the healthcare system. However, there is a gap between what's done in research and clinical practice and researchers and clinicians need to work together to understand how to make the most of the new spatial omics methods. I believe we will reach faster implementation to improve the life of patients if we work together across the disciplines as a team science effort.

### The Future of Spatial Technologies in Precision Medicine

The success and sustainability of spatial technologies in the clinical setting depend on several key factors. Firstly, these technologies must be robust, scalable, and easily implemented. Clinicians require streamlined protocols that can be seamlessly integrated into their existing workflows. The automation of data analysis and interpretation is crucial to ensure efficiency and reliability in clinical practice.

Furthermore, collaboration between researchers, clinicians, and regulatory bodies is essential for driving the adoption of spatial technologies. By working together, these stakeholders can establish guidelines, validate methodologies, and develop standardized approaches for the implementation of spatial technologies. Open communication and knowledge exchange will accelerate the translation of research findings into clinical applications, ultimately benefiting patients worldwide.

### Final Remarks from Dr Stadler:

Stadler adds that spatial technologies have the potential to revolutionize precision medicine by providing clinicians with a deeper understanding of disease mechanisms and treatment response. These technologies enable personalized treatment strategies, improve patient outcomes, and enhance the overall efficiency of healthcare delivery. While challenges exist, the adoption of spatial technologies in the clinical setting is driven by proven needs, cost-effectiveness, and the desire to provide the best possible care to patients. As research progresses and collaborations flourish, spatial technologies will continue to accelerate the advancement of precision medicine, transforming the way diseases are diagnosed and treated.





## Miao-Ping Chien, Associate Professor, Erasmus University Medical Center; Oncode Institute

Miao-Ping Chien delves into the world of spatial biology technology, exploring its potential applications in clinical settings and the challenges that researchers are currently facing. Spatial omics technologies have gained significant attention in recent years, both in academic research groups and industrial settings. These technologies aim to achieve high-throughput, high-content screening with single-cell or subcellular resolution, capturing a vast amount of transcriptomic data from individual cells. By combining imaging-based methodologies with single-cell sequencing methods, researchers can obtain single-cell resolution with in-depth profiling.

The potential applications of spatial technologies in clinical settings are vast. One area that holds particular promise is oncology. In clinical oncology, the ability to accurately determine the stage and progression of tumors is crucial for effective treatment planning. Pathologists currently rely on general information obtained from tissue slices to assess tumor stage and progression. However, spatial technologies offer a more comprehensive understanding of cancer cells' interactions with their microenvironment, providing additional layers of information for diagnostic and prognostic purposes. The ability to capture rich, in-depth information about individual cells and their molecular profiles is a significant advantage of spatial technologies. This information can help predict disease progression and treatment response, allowing for personalized treatment plans tailored to each patient's specific needs. For example, spatial technologies can identify specific markers expressed in a tumor or patient, which can inform treatment decisions and improve patient outcomes. However, before spatial technologies can be widely adopted in clinical practice, several challenges and barriers need to be addressed.

## TIP 1: Considering the Challenges & Barriers to Adoption

- Technology Development As Chien highlights, one of the main challenges in the adoption of spatial technologies is ensuring their robustness and stability. Researchers need to ensure that the technology can consistently provide accurate and reproducible results across different samples and patients. This requires addressing issues of tissue orientation, reproducibility of data, and matching profiles from different samples. Advances in automation and standardization are key to overcoming these challenges and improving the reliability of spatial technologies.
- Analysis and Interpretation Another significant challenge lies in the analysis and interpretation of spatial data. As spatial technologies generate vast amounts of data, effective analysis methods need to be developed to extract meaningful insights. Standardization of analysis approaches is crucial to ensure reliable and reproducible results across different laboratories and institutions. Additionally, computational techniques and algorithms need to be refined to handle the complexity and volume of spatial data.
- Cost Considerations Dr. Chien believes that the cost of implementing spatial technologies in clinical settings is another barrier to adoption. Currently, the cost of spatial technologies is relatively high, limiting their accessibility and widespread use. To facilitate their adoption, efforts are underway to reduce the cost of spatial technologies without compromising their performance and reliability. As technology advancements continue and economies of scale are achieved, it is expected that the cost of spatial technologies will decrease, making them more affordable for clinical applications.



- Personalized Medicine Chien explains, one of the key driving factors for the adoption of spatial technologies is the potential for personalized medicine. Spatial technologies enable the generation of personalized profiles for individual patients, providing valuable insights into disease progression and treatment response. By analyzing the molecular profiles of tumors and patient cells, clinicians can predict disease outcomes, identify potential metastases, and determine the effectiveness of specific treatments. This personalized approach allows for tailored treatment plans that maximize the chances of successful outcomes for patients.
- Comprehensive Understanding of Disease - Spatial technologies offer a more comprehensive understanding of diseases by capturing detailed information about the interaction between cancer cells and their microenvironment. Chien highlights, this additional layer of information goes beyond the traditional pathology assessments and provides insights into the molecular mechanisms underlying disease progression. By studying the spatial organization of cells and their gene expression patterns, researchers can unravel complex disease processes and identify novel therapeutic targets.
- Improved Diagnostic and Prognostic Capabilities - As Chien mentions, the rich information provided by spatial technologies enhances diagnostic and prognostic capabilities in clinical practice. Traditional diagnostic methods often rely on limited information obtained from tissue slices. In contrast, spatial technologies enable the examination of individual cells, allowing for a more precise assessment









## Miao-Ping Chien, Associate Professor, Erasmus University Medical Center; Oncode Institute

of disease characteristics. By identifying specific molecular markers, clinicians can make more accurate diagnoses and prognoses, guiding treatment decisions and improving patient outcomes.

Advancing Cancer Research – Spatial technologies have the potential to revolutionize cancer research by providing a more comprehensive understanding of tumor heterogeneity. By examining individual cells within a tumor, researchers can identify different cell populations and map their spatial distribution. Chien explains this information is crucial for understanding tumor progression, identifying potential treatment resistance mechanisms, and developing targeted therapies. By accelerating cancer research, spatial technologies have the potential to drive innovation and improve patient outcomes.

## 🐉 TIP 3: Technological Robustness & Feasibility

The development of robust and feasible spatial technologies is crucial for their success in clinical practice. Dr. Chien stresses that researchers need to address the challenges related to technology stability, reproducibility, and automation. Advances in automation and standardization will help minimize manual procedures, reduce variability, and improve the reliability of spatial technologies. By ensuring the robustness and feasibility of spatial technologies, researchers can build confidence among clinicians and regulators, driving their acceptance and integration into clinical practice.

## TIP 4: Standardization & Regulatory Considerations

Chien believes that the standardization of spatial technology protocols and analysis methods is essential for their successful implementation in clinical practice. Regulators require robust and reproducible systems that can deliver consistent results. Standardization efforts should focus on ensuring the reliability, accuracy, and comparability of spatial data across different laboratories and institutions. By meeting regulatory requirements and establishing standardized protocols, spatial technologies can gain acceptance and become an integral part of clinical diagnostics and patient care.

## TIP 5: Cost Reduction and Accessibility

The cost of implementing spatial technologies is a significant consideration for their adoption in clinical settings. To achieve broad accessibility, efforts are needed to reduce the cost of spatial technologies without compromising their performance and reliability. As technology advancements continue and economies of scale are achieved, the cost of spatial technologies is expected to decrease, making them more accessible to healthcare providers and patients. Cost reduction will be a key factor in driving the widespread adoption of spatial technologies in clinical practice.

## Final Remarks by Dr. Chien:

As Chien emphasises, spatial biology technology holds great promise for advancing clinical applications in various fields, particularly in oncology. By combining imaging-based methodologies with single-cell sequencing methods, researchers aim to capture comprehensive, in-depth information about individual cells and their molecular profiles. Spatial technologies have the potential to revolutionize clinical practice by enabling personalized medicine, providing a comprehensive understanding of diseases, and improving diagnostic and prognostic capabilities. While spatial technologies face several challenges and barriers, ongoing efforts in technology development, analysis, and cost reduction are driving their adoption in clinical settings. The success and sustainability of spatial technologies depend on robustness, standardization, and accessibility. By addressing these key factors, spatial technologies can become an integral part of routine clinical workflows, improving patient outcomes and driving innovation in healthcare.

As spatial technologies continue to evolve, it is crucial for researchers, clinicians, and regulators to collaborate and embrace the advancements in this field. By harnessing the full potential of spatial biology technology, we can unlock new insights into disease mechanisms, develop targeted therapies, and ultimately improve patient care. The future of spatial technologies in clinical practice is promising, and the journey towards their widespread adoption is underway.







# JOHN WATERTON, Professor, The University of Manchester

## **TIP 1:** Advancing Biomarker Development

As Waterton explains, spatial technologies can provide sensitive and specific biomarkers. In early-phase clinical trials, spatial biomarkers offer insights at a cellular and molecular level, invaluable in verifying mechanism of action, dosefinding and perhaps identifying safety issues. Such biomarkers can help drug developers make informed decisions, thereby reducing costly failure rates in Phase 3.

## **TIP 2:** Personalized Medicine and **Treatment Tailoring**

Waterton believes that spatial technologies can play a significant role in personalized medicine. When patients have multiple treatment options, as with immunotherapies in oncology or rheumatoid arthritis, innovative spatial technologies can provide companion diagnostics to choose the safest and most efficacious option and provide drug developers with more cost-effective routes to market.

## **TIP 3:** Navigating Regulatory Challenges

The integration of spatial technologies into drug development and patient care requires meticulous attention to regulatory expectations. Technology developers need to navigate the contradiction between innovation and regulation. As Waterton stresses, regulatory bodies expect biomarkers to provide robust, standardized, and reproducible data. In particular, the definition of the biomarker metric, analysis







platform and algorithms must be rigorously established at the outset, then frozen, maybe for many years.

## TIP 4: Strategic Partnerships and Financial Support

Waterton notes that transitioning from academic research to clinical applications necessitates substantial investments.

Strategic collaborations with pharmaceutical companies can help transform spatial metrics into pharmacodynamic biomarkers, ensuring that the technology aligns with industry requirements, while venture capitalists can provide investment needed for research, development, and global marketing of predictive biomarkers and companion diagnostics.

## **TIP 5: Managing Long-term Expectations**

Waterton points out that, while the potential of spatial technologies is transformative, managing expectations is crucial. Timeline for translating research breakthroughs into impactful clinical tools can protracted, and many years may be needed to demonstrate how a standardised spatial biomarker actually improves patient outcomes. Researchers, investors, and other stakeholders must embrace the long-term nature of such translational efforts.

## Final Remarks by Dr. Waterton:

Spatial biomarkers provide a new dimension in innovation, research, drug development and personalised healthcare. Their potential to enhance patient outcomes is profound. To realize this potential fully, a translational approach, encompassing technology refinement, regulatory alignment, strategic partnerships, and realistic, long-term goals is imperative.



## NAVIGATING THE PHARMA R&D **REGULATORY LANDSCAPE NOW AVAILABLE**

FOR MORE INFORMATION CLICK HERE



